Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Receivables (2018 - 2025)

AVITA Medical (RCEL) has disclosed Receivables for 5 consecutive years, with $9.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables fell 22.91% year-over-year to $9.1 million, compared with a TTM value of $9.1 million through Dec 2025, down 22.91%, and an annual FY2025 reading of $9.1 million, down 22.91% over the prior year.
  • Receivables was $9.1 million for Q4 2025 at AVITA Medical, up from $9.0 million in the prior quarter.
  • Across five years, Receivables topped out at $12.0 million in Q1 2025 and bottomed at $3.5 million in Q4 2022.
  • Average Receivables over 4 years is $7.4 million, with a median of $7.4 million recorded in 2023.
  • The sharpest move saw Receivables skyrocketed 118.89% in 2023, then fell 22.91% in 2025.
  • Year by year, Receivables stood at $3.5 million in 2022, then surged by 118.89% to $7.7 million in 2023, then soared by 53.18% to $11.8 million in 2024, then dropped by 22.91% to $9.1 million in 2025.
  • Business Quant data shows Receivables for RCEL at $9.1 million in Q4 2025, $9.0 million in Q3 2025, and $11.3 million in Q2 2025.